JNJ Pipeline Data Shines Amid Talc Verdict Pressure

Johnson & Johnson ($JNJ) presented comprehensive Phase 2/3 ENERGY study results showing $JNJ IMAAVY (nipocalimab-aahu) produced statistically significant durable hemoglobin response with rapid onset in patients with warm autoimmune hemolytic anemia in the 30 mg/kg treatment group compared with placebo. The randomized, placebo-controlled trial demonstrated approximately three times as many patients achieved durable response versus placebo in a disease with no FDA-approved therapies. $JNJ is investing $1 billion in hard-to-treat cancer programs as shares climb back toward record territory while technology stocks sell off. Gilead Sciences ($GILD) announced topline Phase 3 IDEAL study results showing Livdelzi (seladelpar) led to significantly more patients achieving endpoints in primary biliary cholangitis treatment. Eli Lilly ($LLY) received FDA approval for extended once-every-eight-weeks maintenance dosing for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis, expanding the company's dermatology footprint beyond obesity and diabetes franchises with broad pharmacy benefit manager coverage already secured.

Abbott Laboratories ($ABT) secured European CE Mark approval for Libre Duo, described as the world's first dual glucose and ketone continuous monitoring sensor, and entered an expanded agreement with MiniMed on June 3 to commercialize dual glucose-ketone sensors for integration with MiniMed smart dosing systems. $ABT presented data at the American Diabetes Association's 2026 Scientific Sessions on diabetic ketoacidosis risk and outcomes from its Healthy Food Rx program for people with type 2 diabetes. The American Cancer Society reaffirmed $ABT Cologuard and Cologuard Plus as preferred options in updated US colorectal cancer screening guidelines. Shares closed at $89.17, down 2.28% from the previous trading day. Shockwave Medical, now part of $JNJ, discussed competitive positioning in intravascular lithotripsy after becoming first to market in the space with strong uptake.

UnitedHealth Group ($UNH) received a reset stock target from JPMorgan for 2026 as the company continues recovering from severe volatility experienced one year ago when shares traded at approximately $300 to $312 per share, down from an all-time closing high of $603.20 in November 2024. CEO Andrew Witty had stepped down during that period and the company pulled guidance amid the downturn. $UNH closed at $407.73, down 1.28% from the prior session, reflecting continued stabilization after the leadership transition and operational reset.

RBC Capital upgraded Pfizer ($PFE) to Sector Perform from Underperform while maintaining a $25 price target after the stock's approximately 11% pullback from 2026 highs brought valuation in line with expectations and reduced downside risks the firm had previously highlighted. The upgrade signals a stabilizing outlook ahead of key pipeline catalysts following the 2026 selloff. Thermo Fisher Scientific ($TMO) delivered a strong Q1 2026 earnings beat and raised full year guidance while showcasing new high sensitivity Orbitrap mass spectrometers and AI-driven proteomics software at the ASMS conference, though shares remain down 18.64% year-to-date despite a 16.54% total shareholder return over the past year. Cancer drug developer Parabilis priced its IPO above range and raised nearly $745 million after demand reached about 10 times available shares.

A Los Angeles jury found Johnson & Johnson ($JNJ) and its subsidiaries liable in a talc trial linked to mesothelioma, awarding $32 million to the family of a woman whose fatal illness was tied to long-term use of the company's talc-based baby powder. The verdict adds to ongoing legal and reputational pressure surrounding historical talc products and alleged asbestos contamination. Despite the legal headwind, $JNJ stock has climbed back toward record territory as the diversified healthcare company advances its pharmaceuticals, medical devices, and consumer health divisions.